[Differential diagnosis and treatment of nausea and vomiting associated with cancer or its treatment] [0.03%]
[与癌症或治疗相关的恶心和呕吐的鉴别诊断及处理]
Csaba Simkó
Csaba Simkó
Nausea and vomiting are frequent and fearful issues both of cancer itself and its treatment, resulting in reduced quality of life, hospitalization and unnecessary medical investigations. Unconventionally, the author discusses the treatment-...
András Telekes
András Telekes
The evolution of medicine is noticeable in most therapeutic areas, the worse the current therapeutic result, the more quick the improvement. This is especially true in such areas that require substantial social resources, namely oncology, d...
József Lövey
József Lövey
The majority of cancer patients becomes malnourished during the course of their disease. Malnutrition deteriorates the efficiency of all kinds of oncologic interventions. As a consequence of it, treatment-related toxicity increases, hospita...
Csaba András Nagy,Mária Lódi,Ingrid Balogh et al.
Csaba András Nagy et al.
It is well-known that modern oncotherapy significantly reduced the mortality of malignant diseases. However, serious side effects of the applied cancer therapies have evolved, which may adversely affect the cardiovascular system. Early side...
László Landherr,Tamás Nagykálnai
László Landherr
Some disseminated tumor cells (as "seeds") feel well in the skeletal tissue, as a "soil", but the humoral crosstalk between tumor cells and bone cells disrupts the normal bone homeostasis (remodeling), which leads to a vicious circle, the m...
Review
Magyar onkologia. 2017 Jun 6;61(2):175-180. DOI: 2017
[Palbociclib combinations as new therapeutic strategies in the treatment of HR+/HER2- advanced breast cancer] [0.03%]
帕博西尼联合用药在HR+/HER2-晚期乳腺癌治疗中的新策略研究
Katalin Boér
Katalin Boér
Until recently, the only endocrine agents used to treat HR+/HER2- advanced breast cancers were tamoxifen, aromatase inhibitors and fulvestrant, although a substantial proportion of patients relapse on these standard therapies. Intensive res...
Review
Magyar onkologia. 2017 Jun 6;61(2):167-173. DOI: 2017
[Predictive markers of immunotherapy of cancer, practical issues of PD-L1 testing] [0.03%]
[癌症免疫治疗的预测标志物及PD-L1检测的实际问题]
József Tímár,Andrea Ladányi
József Tímár
Pathologists have detected signs of antitumor immune reactions for a long time but only in case of a few cancer types became this part of the report. The advent of immunotherapy of cancers, however, radically alters this routine and promote...
Review
Magyar onkologia. 2017 Jun 6;61(2):158-166. DOI: 2017
Gyula Ostoros
Gyula Ostoros
Similarly to other malignancies, immune checkpoint inhibitor therapy is a revolutionary, effective new treatment possibility for lung cancer. In lung cancer carcinogenesis is related mainly to tobacco smoking with high somatic mutation rate...
Review
Magyar onkologia. 2017 Jun 6;61(2):153-157. DOI: 2017
György Bodoky
György Bodoky
Immunotherapy proved to be effective in various forms of cancer but it is in its infancy in colorectal cancer, although the Immunoscore was developed to classify this tumor immunologically. Various forms of immunotherapy were tested in earl...
Review
Magyar onkologia. 2017 Jun 6;61(2):147-151. DOI: 2017
[The role of immunotherapy in the modern treatment of urothelial carcinoma] [0.03%]
[免疫治疗在现代尿路上皮癌治疗中的作用]
Anikó Maráz,Lajos Géczi
Anikó Maráz
By the emergence of modern immunotherapies with active agents like PD-1 (nivolumab, pembrolizumab) and PD-L1 immune checkpoint blockers (atezolizumab, avelumab, durvalumab), new therapeutic options have become available for the treatment of...
Review
Magyar onkologia. 2017 Jun 6;61(2):139-146. DOI: 2017